Total Payments
$13,990
2024 Payments
$22.13
Companies
13
Transactions
43
Payment Breakdown by Category
Research$11,422 (81.6%)
Food & Beverage$2,486 (17.8%)
Education$82.48 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,422 | 13 | 81.6% |
| Food and Beverage | $2,486 | 25 | 17.8% |
| Education | $82.48 | 5 | 0.6% |
Payments by Type
Research
$11,422
13 transactions
General
$2,569
30 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $10,041 | 2 | $0 (2019) |
| SANOFI US SERVICES INC. | $1,257 | 9 | $0 (2023) |
| Novo Nordisk Inc | $1,161 | 13 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $320.52 | 3 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $233.39 | 4 | $0 (2018) |
| Lilly USA, LLC | $188.62 | 3 | $0 (2019) |
| Amarin Pharma Inc. | $131.82 | 2 | $0 (2018) |
| Cardiovascular Systems Inc. | $125.00 | 1 | $0 (2018) |
| Eli Lilly and Company | $124.10 | 2 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $118.44 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22.13 | 1 | Novo Nordisk Inc ($22.13) |
| 2023 | $1,257 | 9 | SANOFI US SERVICES INC. ($1,257) |
| 2022 | $12.00 | 1 | Eli Lilly and Company ($12.00) |
| 2021 | $118.44 | 1 | Janssen Pharmaceuticals, Inc ($118.44) |
| 2020 | $112.10 | 1 | Eli Lilly and Company ($112.10) |
| 2019 | $10,368 | 6 | Bausch Health US, LLC ($10,041) |
| 2018 | $1,141 | 12 | Novo Nordisk Inc ($577.44) |
| 2017 | $960.47 | 12 | Novo Nordisk Inc ($449.68) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/27/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Diabetes | ||||||
| 11/15/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $479.12 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 11/15/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $136.26 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 11/15/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $107.92 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 11/15/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $73.58 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 11/15/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $60.00 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 11/14/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $124.94 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 11/14/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $75.01 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 11/14/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $60.00 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 11/13/2023 | SANOFI US SERVICES INC. | — | — | In-kind items and services | $139.98 | Research |
| Study: Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | ||||||
| 04/06/2022 | Eli Lilly and Company | — | — | In-kind items and services | $12.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 06/08/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $118.44 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/06/2020 | Eli Lilly and Company | — | — | In-kind items and services | $112.10 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 11/21/2019 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Drug), SOLIQUA 100/33 | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: DIABETES | ||||||
| 10/27/2019 | Bausch Health US, LLC | TRULANCE (Drug) | — | Cash or cash equivalent | $7,870.95 | Research |
| Study: A Randomized, Double Blind, Placebo-controlled, Dose Ranging, Parallel-group study of the Efficacy and Safety of Plecanatide in Chinldren 6 to 18 Years of Age with Irritable Bowel Syndrome with Constipation IBS-C • Category: GASTROENTEROLOGY | ||||||
| 10/03/2019 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $73.87 | General |
| Category: Diabetes | ||||||
| 10/03/2019 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Diabetes | ||||||
| 08/10/2019 | Bausch Health US, LLC | TRULANCE (Drug) | — | Cash or cash equivalent | $2,169.90 | Research |
| Study: A Randomized, Double Blind, Placebo-controlled, Dose Ranging, Parallel-group study of the Efficacy and Safety of Plecanatide in Chinldren 6 to 18 Years of Age with Irritable Bowel Syndrome with Constipation IBS-C • Category: GASTROENTEROLOGY | ||||||
| 05/14/2019 | Novo Nordisk Inc | Xultophy 100/3.6 (Drug) | Food and Beverage | In-kind items and services | $111.68 | General |
| Category: Diabetes | ||||||
| 12/04/2018 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $124.85 | General |
| Category: Diabetes | ||||||
| 10/17/2018 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $97.66 | General |
| Category: Diabetes | ||||||
| 09/05/2018 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Diabetes | ||||||
| 08/30/2018 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $112.51 | General |
| Category: Diabetes | ||||||
| 07/24/2018 | Arthrosurface Incorporated | HemiCAP Shoulder (Device) | Food and Beverage | In-kind items and services | $102.44 | General |
| Category: Musculoskeletal | ||||||
| 05/30/2018 | Cardiovascular Systems Inc. | Peripheral Orbital Atherectomy System (Device) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Atherectomy Device | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double Blind, Placebo-controlled, Dose Ranging, Parallel-group study of the Efficacy and Safety of Plecanatide in Chinldren 6 to 18 Years of Age with Irritable Bowel Syndrome with Constipation IBS-C | Bausch Health US, LLC | $10,041 | 2 |
| Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | SANOFI US SERVICES INC. | $1,257 | 9 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $112.10 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $12.00 | 1 |
About Dr. Manuel Sanchez, MD
Dr. Manuel Sanchez, MD is a General Practice healthcare provider based in Hialeah, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427118165.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Manuel Sanchez, MD has received a total of $13,990 in payments from pharmaceutical and medical device companies, with $22.13 received in 2024. These payments were reported across 43 transactions from 13 companies. The most common payment nature is "" ($11,422).
Ad
Practice Information
- Specialty General Practice
- Location Hialeah, FL
- Active Since 12/11/2006
- Last Updated 11/03/2009
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1427118165
Products in Payments
- TRULANCE (Drug) $10,041
- Tresiba (Drug) $443.34
- Ozempic (Drug) $357.15
- UTIBRON (Drug) $228.42
- SOLIQUA (Drug) $195.53
- TRULICITY (Drug) $188.62
- Vascepa (Drug) $131.82
- Peripheral Orbital Atherectomy System (Device) $125.00
- TOUJEO (Drug) $124.99
- XARELTO (Drug) $118.44
- Xultophy 100/3.6 (Drug) $111.68
- HemiCAP Shoulder (Device) $102.44
- JARDIANCE (Drug) $100.62
- Claria MRI (Device) $86.95
- Victoza (Drug) $78.23
- SEEBRI (Drug) $4.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Hialeah
Daniel Basulto, Md, MD
General Practice — Payments: $31,814
General Practice $31,814
Mr. Julian Marquez, Md, MD
General Practice — Payments: $30,111
General Practice $30,111
Dr. Jose Gonzalez, M.d, M.D
General Practice — Payments: $30,071
General Practice $30,071
Gilda De La Calle, Md, MD
General Practice — Payments: $26,563
General Practice $26,563
Dr. Javier Ricardo, Md, MD
General Practice — Payments: $23,177
General Practice $23,177
Gladys Alonso, Md, MD
General Practice — Payments: $16,533
General Practice $16,533